INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

NCT04702893 · clinicaltrials.gov ↗

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Diseases, Interstitial

Interventions

DRUG: Nintedanib

Sponsor

Boehringer Ingelheim